Evergreen Capital Management LLC Increases Position in Glaukos Co. (NYSE:GKOS)

Evergreen Capital Management LLC increased its position in shares of Glaukos Co. (NYSE:GKOS) by 5.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,472 shares of the medical instruments supplier’s stock after purchasing an additional 177 shares during the period. Evergreen Capital Management LLC’s holdings in Glaukos were worth $521,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Harbor Capital Advisors Inc. purchased a new position in shares of Glaukos in the fourth quarter valued at about $3,679,000. Sanctuary Advisors LLC bought a new stake in Glaukos during the 3rd quarter valued at approximately $258,000. Rhumbline Advisers raised its stake in Glaukos by 0.3% during the 4th quarter. Rhumbline Advisers now owns 141,790 shares of the medical instruments supplier’s stock valued at $21,260,000 after purchasing an additional 403 shares during the period. IFP Advisors Inc purchased a new position in Glaukos in the 4th quarter worth approximately $43,000. Finally, US Bancorp DE boosted its stake in Glaukos by 8.3% in the 4th quarter. US Bancorp DE now owns 6,099 shares of the medical instruments supplier’s stock worth $914,000 after purchasing an additional 470 shares during the period. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Glaukos Stock Performance

NYSE GKOS opened at $90.15 on Friday. The business’s 50 day moving average price is $109.20 and its 200-day moving average price is $131.61. Glaukos Co. has a fifty-two week low of $77.91 and a fifty-two week high of $163.71. The company has a market cap of $5.10 billion, a P/E ratio of -31.41 and a beta of 0.88. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The firm had revenue of $105.50 million for the quarter, compared to the consensus estimate of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. Sell-side analysts predict that Glaukos Co. will post -1.08 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the stock. Stifel Nicolaus boosted their target price on shares of Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, December 31st. Needham & Company LLC boosted their price target on shares of Glaukos from $149.00 to $176.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Wells Fargo & Company raised their price objective on Glaukos from $153.00 to $160.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Mizuho decreased their target price on Glaukos from $200.00 to $175.00 and set an “outperform” rating on the stock in a research report on Wednesday. Finally, Truist Financial cut their price target on Glaukos from $185.00 to $140.00 and set a “buy” rating for the company in a report on Friday, April 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $156.17.

Insider Buying and Selling

In other news, CFO Alex R. Thurman sold 1,520 shares of the company’s stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the transaction, the chief financial officer now directly owns 53,431 shares in the company, valued at approximately $5,708,568.04. This represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Tomas Navratil sold 3,416 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares in the company, valued at $10,658,380.18. This represents a 4.50 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by corporate insiders.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.